Objective: to investigate the distribution of candidiasis in patients with vulvovaginal candidiasis (VVC) in Baotou area and the susceptibility to antifungal drugs, so as to provide reference for accurate clinical treatment. Methods: The vaginal secretions of 295 patients with VVC from January to December 2021 were collected for isolation and culture. MALDI-TOFMS and PCR were used to complete the identification of strains. According to the CLSI M27-S4 standard, the in vitro drug sensitivity test of 9 drugs was carried out by microbroth dilution method. Results: The patients with infection were most common in the 31-35 age group (30.85%), followed by the 26-30 age group (20.34%), and the 21-40 age group accounted for 82.04%. Sexual life, pregnancy and other susceptible factors accounted for a large proportion in VVC. A total of 295 non-repetitive strains were isolated and identified, of which Candida albicans ranked the first (79.32%), followed by Candida glabrata (13.90%), and 7 rare Candida species such as Nivalia and Bugala (1 strain in each). The resistance rate of Candida albicans to itraconazole was higher than that of non-Candida albicans (P＜0.01), while there was no significant difference in the resistance of fluconazole, voriconazole and posaconazole between the two groups (P＞0.05). The resistance rate of non-Candida albicans to caspofungin and 5-fluorocytosine was higher than that of Candida albicans (P＜0.01). No nystatin-resistant strains were found. The sensitivity of all strains to amphotericin B was 100%, and the resistance rate to terbinafine was high. Conclusion: VVC patients in Baotou area are infected with various strains, especially Candida albicans, but the susceptibility of different strains to common antifungal drugs is quite different. Regular and continuous drug resistance monitoring should be carried out to guide gynecologists to formulate correct diagnosis and treatment plans and delay the emergence of drug resistance.
WANG Na
,
ZHANG Lixia
,
HU Tongping
,
WANG Zhanli
,
SHI jihai
,
GUO Lina
,
YI Xingchi
,
LI Hongyu
. Strain distribution and drug susceptibility analysis of 295 VVC isolates in Baotou area[J]. Journal of Baotou Medical College, 2024
, 40(2)
: 32
-38
.
DOI: 10.16833/j.cnki.jbmc.2024.02.006
[1] 高月倩,白君宜,王辰,等. 2021年美国疾病控制和预防中心《性传播感染治疗指南》关于阴道炎症的诊治规范解读[J]. 中国实用妇科与产科杂志,2021,37(11):1141-1146.
[2] Khorsand I,Ghanbari Nehzag MA,Zarrinfar H,et al. Frequency of variety of Candida species in women with Candida vaginitis referred to clinical centers of Mashhad, Iran[J].Iran J Obstet Gynecol Infertil,2015,18(168):15-22.
[3] Minooeianhaghighi MH , Sehatpour M, Zarrinfar H, et al. Recurrent vulvovaginal candidiasis: the causative agents, clinical signs and susceptibility to fluconazole in gonabad city, northeast Iran[J].Current Women's Health Reviews, 2020,16(1):46-51.
[4] Performance Standards for Antifungal Susceptibility Testing of Yeasts - 1st Edition: CLSI M60-Ed1[S]. Clinical And Laboratory Standards Institute [clsi].
[5] CLSI M27-2017.Reference method for broth dilution antifungal susceptibility testing of yeasts[S].2017.
[6] CLSI M59-2018.Clinical and laboratory standards institute.epidemiological cutoff values for antifungal susceptibility testing[S].2018.
[7] 马晓彤,李焕荣,王慧慧,等. 阴道微生态理论应用于外阴阴道假丝酵母菌病的研究进展[J]. 中华妇产科杂志,2020,55(4):284-286.
[8] 肖盟. 中国侵袭性酵母菌病病原菌的流行病学及药物敏感性研究[D]. 北京:北京协和医学院,2014.
[9] Venugopal D, Husain K, Mustafa SA, et al. Epidemiology, risk factors and antimicrobial profile of Vulvovaginal Candidiasis (VVC):a study among women in the central region of Saudi Arabia[J]. J Mycol Med, 2021,31(2):101049.
[10] Hashemi SE, Shokohi T, Abastabar M, et al. Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae[J]. Curr Med Mycol, 2019,5(4):26-34.
[11] 范琳媛,白会会,刘朝晖,等. 544例外阴阴道假丝酵母菌病患者阴道微生态和菌种药物敏感性分析[J]. 现代妇产科进展,2020,29(10):748-751.
[12] 雷岩,陈晓菲,晏亮,等. 289株VVC致病菌的菌种分布和对9种抗真菌药物敏感性[J]. 菌物学报,2019,38(8):1306-1313.
[13] Kan S, Song N, Pang Q, et al.In vitro antifungal activity of azoles and other antifungal agents against pathogenic yeasts from vulvovaginal candidiasis in China[J]. Mycopathologia, 2023,188(1/2):99-109.
[14] Rolo J, Faria-Gonçalves P, Barata T, et al. Species distribution and antifungal susceptibility profiles of isolates from women with nonrecurrent and recurrent vulvovaginal candidiasis[J]. Microb Drug Resist, 2021,27(8):1087-1095.
[15] Anh DN, Hung DN, Tien TV, et al. Prevalence, species distribution and antifungal susceptibility of Candida albicans causing vaginal discharge among symptomatic non-pregnant women of reproductive age at a tertiary care hospital, Vietnam[J]. BMC Infect Dis, 2021,21(1):523.
[16] Urbanek AK, Łapińska Z, Derkacz D, et al. The role of ERG11 point mutations in the resistance of Candida albicans to fluconazole in the presence of lactate[J]. Pathogens, 2022,11(11):1289.
[17] Boikov DA, Locke JB, James KD, et al.In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis[J]. J Antimicrob Chemother, 2017,72(5):1355-1358.
[18] Ghaddar N, Anastasiadis E, Halimeh R, et al. Prevalence and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant women in Lebanon[J]. BMC Infect Dis, 2020,20(1):32.
[19] Wang FJ, Zhang D, Liu ZH, et al. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China[J]. Chin Med J, 2016,129(10):1161-1165.
[20] Hong N, Lei Y, Chen H, et al. Genotyping and drug resistance profile of clinical isolates of Candida albicans from vulvovaginal candidiasis in the eastern China[J]. Mycopathologia, 2022,187(2/3):217-224.
[21] Gorgun S, Bilgin M, Kilic SS. Distribution and antifungal susceptibility of candida species isolated from blood cultures[J]. J Pak Med Assoc, 2021,71(6):1601-1604.
[22] Jørgensen KM, Astvad KMT, Hare RK, et al. EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mold and yeast isolates[J]. Antimicrob Agents Chemother, 2019,63(6):e00073-e00019.
[23] Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009,48(5):503-535.
[24] Sharifynia S, Rezaie S, Mohamadnia A, et al. Genetic diversity and antifungal susceptibility of Candida albicans isolated from Iranian patients[J]. Med Mycol, 2019,57(1):127-131.
[25] 张欠欠,罗传玉,陈嘉琪,等. 白念珠菌感染现状及抗真菌药物研究进展[J]. 中国真菌学杂志,2021,16(5):356-360.
[26] Yassin MT, Mostafa AA, Al-Askar AA, et al.In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis[J]. Eur J Med Res, 2020,25(1):1.
